Univercells Technologies, a Donaldson Life Sciences company and global provider of bioprocessing solutions, has launched the scale-X nitro controller, the latest addition to its scale-X fixed-bed bioreactor portfolio.

Designed to operate both the 200 and 600 m² scale-X nitro bioreactors, the new controller offers a cost-effective, low-footprint, and user-friendly solution for large-scale viral and advanced therapy manufacturing, delivering high productivity and enabling rapid scalability from R&D to commercial production in just eight months.

The new controller complements the existing NevoLine bioreactor platform by providing an alternative for developers and manufacturers looking to achieve high-productivity viral manufacturing with simplified operations. Supporting both adherent and suspension cell cultures, it is suited for a wide range of applications including viral vaccines, exosomes, LV and AAV vector production, oncolytic viruses, and recombinant proteins.

“When we introduced the scale-X portfolio, our goal was to create a high-performing, cost-effective and scalable solution that could take users from early R&D through to GMP and commercial scale,” said Marie Jourdan, Director of the Bioprocessing Product Portfolio at Univercells Technologies. “This launch completes that vision. The new controller makes it possible for biotech and biopharma companies, CDMOs, and academic institutions to scale up without added complexity or cost.”

With this launch, Univercells Technologies further strengthens its commitment to delivering scalable, accessible solutions for advanced therapy and vaccine developers worldwide.